Recurrent Pterygium Eye Diseases Conjunctiva disorders
Conditions
Interventions
Twenty-nine patients were randomly divided into three groups according to random numbers:
Group one: Nine patients submitted to CAT, using Placebo Eye-Drops (PED) 14 days before the surgery.
Group t
Sponsors
Foundation for the Support of Education and Research (Fundação de Apoio ao Ensino, Pesquisa e Extensão [FAEPE]) (Brazil)
Eligibility
Inclusion criteria
Inclusion criteria: Patients who presented symptoms of ocular irritation, photophobia and burning pain all concomitant with corneal invasion with more than 3 mm horizontal length, measured starting from the anatomical limbus.
Exclusion criteria
Exclusion criteria: 1. Patients with: a. keratoconjuntivitis sicca b. Sjögren disease c. vernal keratoconjunctivitis d. acne rosacea e. neurothrophic keratopathy f. severe dysfunction of the meibomius glands; patients with meibomius gland dysfunction with clinical indications (symptoms and signs), mild to moderate, were previously treated 2. Patients that use any immunosuppressive drug, through systemic and topical administration 3. Patients aged less than 18 years of age and vulnerable groups 4. Associated glaucoma and the use of ocular hypotensor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The recurrence rate after six months follow-up 2. The epithelial cell proliferative activity using as marker the antigen Ki-67 3. Fibroblasts nucleus cariometry to evaluate the area and volume of the nucleus | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the safety and efficacy of MMC used topical or subconjunctival route before the surgery treatment of pterygium | — |
Countries
Brazil
Outcome results
None listed